People · Operator
Named in public records as an officer, director or promoter · active 2010–2023 · Other Technology, Pharmaceuticals, Biotechnology, Investment Vehicle, Restaurants, Other
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Casters Holdings Inc | — | Other Technology | Series C | $80.3M | $34.0M | 2020 |
| Equilibre BioPharmaceuticals Corp. | — | Pharmaceuticals | Series B | $47.7M | $79.7M | 2020 |
| Genprex, Inc. | — | Biotechnology | Series A | $14.6M | $52.7M | 2013 |
| Panther Opportunity Fund, Llc | — | Investment Vehicle | Series A | $10.0M | $151.3M | 2017 |
| Epic Burger, Inc. | — | Restaurants | Seed | $6.9M | $1.8M | 2010 |
| PKLYN ONE Holdings LLC | — | Other | Seed | $2.8M | $14.4M | 2023 |
| VividGro, Inc. | — | Other Technology | Seed | $2.4M | $81.8M | 2018 |
| Hero Network, Inc. | — | Other Technology | Seed | $1.7M | $5.4M | 2013 |
| AgTech Holdings, Inc. | — | Agtech / Foodtech | Pre-Seed | $1000K | $9.8M | 2021 |
David Friedman at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside David Friedman on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Chad Bronstein | 1 | 9 |
| Joel Marcus | 1 | 9 |
| Mitchell Baruchowitz | 1 | 8 |
| Mitchell Kahn | 1 | 7 |
| James Everett | 1 | 6 |
| Anthony K. Tjan | 1 | 6 |
| Peter Simon | 1 | 6 |
| Adam Arviv | 1 | 4 |
| Steven N Gordon | 1 | 3 |
| John D. Hamel | 1 | 3 |
| Philip Barach | 1 | 3 |
| Mamta Patel | 1 | 3 |
| CRAIG ROBINSON | 1 | 3 |
| Steven Gordon | 1 | 3 |
| Clive Sirkin | 1 | 3 |
| Abraham Morris | 1 | 3 |
| Samuel Waksal | 1 | 2 |
| David Girgenti | 1 | 2 |
| John Rodney Varner | 1 | 2 |
| David E Friedman | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.